Wirtschaftswoche: Cell of Profit

In the lastest edition of “Wirtschaftswoche (WiWo)” we have been mentioned. You can find the entire article over here:

To the article

© Handelsblatt GmbH. All Rights reserved.

Zyagnum company of the year 2018

District Administrator Klaus Peter Schellhaas at the presentation of the certificate “Unternehmen des Jahres 2018” about Zyagnum:

“An example of outstanding innovations, useful for many people, paired with a well thought-out sales structure is provided by Zyagnum AG in Pfungstadt. Serious illnesses like cancer can affect you in every stage of your life. Screening procedures have been established so that diseases can be detected as early as possible: every early detection of tumors improves the chances of recovery. Grown up from a biotech company founded in 2007 and located near the Pfungstädter Biopharm, the Zyagnum AG in Pfungstadt positions the new, universal cancer test “PanTumDetect”. Zyagnum AG is an innovative technology company that develops diagnostics together with competent partners in order to enable targeted treatment for all patients worldwide at an early stage..”

The award ceremony took place as part of an event organized by the district of Darmstadt-Dieburg. Three companies were awarded for outstanding innovations and entrepreneurial investments to secure and create jobs in the district of Darmstadt-Dieburg.

Landkreis Darmstadt-Dieburg: (left to right) Patrick Koch (mayor Pfungstadt), Landrat Klaus Peter Schellhaas, Dr. Oliver Feyen and CEO Ralf Schierl (Zyagnum AG), Dr. Carsten Bruns (CEO r-biopharm AG)

Zyagnum supports children in need in Thailand

Together with the GESINAS Foundation, Zyagnum supports the expansion of the kindergarten in the Ban Nam Som School in Thailand. Thanks to this donation and the tireless commitment of Werner Luttmann (Immunotools) in the foundation, the construction of the kindergarten in Wat Chan has already been completed.

For more information click here and here  or:

Facebook Raintree Foundation
Facebook Thai Care e.V.

Validation EDIM blood test in Tübingen started

The EDIM test was established at the University of Tübingen under Prof. Handgretinger, Medical Director General Paediatrics, Haematology / Oncology Children’s hospital Tübingen. Since then, samples of patients with various tumors have been examined daily. It has been shown that the EDIM test has previously identified all tumors, regardless of the tumor entity, and is characterized by very good sensitivity and specificity. First data have already been presented or published at congresses.

  • Grimm, M.; Schmitt, S.; Teriete, P.; Biegner, T.; Stenzl, A.; Hennenlotter, J.; Muhs, H.J.; Munz, A.; Nadtotschi, T.; König, K.; et al.
    A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. 
    BMC Cancer 2013, 13, 569. [PubMed]
  • press release University Hospital Tübingen

Universal cancer test: meaning and function of used marker TKTL1 has been clearly demonstrated

In the EDIM detect, the markers TKTL1 and Apo10 are used.

Both biomarkers detect fundamental biophysical mechanisms that are significantly altered in all forms of malignancy (Grimm et al., 2013).

All forms of tumour cells exhibit a disorder in the process of the planned cell death (apoptosis). Only when this process is disturbed and as a result of which the cell no longer kills itself can a tumour cell form. This apoptosis can be detected with Apo10.

TKTL1 shows the change of energy generation from oxidative phosphorylation to fermentative energy release. This is also a fundamental biophysical process that can be used by all tumour cells, regardless of their entity. The activation of the TKTL1 gene in tumour cells leads to a fermentative, oxygen-independent metabolism which is accompanied by an increased uptake of glucose, an enhanced formation of lactic acid and the capacity for invasive growth.

The meaning and function of TKTL1 has been clearly demonstrated with the latest publication (Jayachandran et al., 2016 / Diaz-Morali et al., 2016).

  • Jayachandran, A.; Lo, P.H.; Chueh, A.C.; Prithviraj, P.; Molania, R.; Davalos-Salas, M.; Anaka, M.; Walkiewicz, M.; Cebon, J.; Behren, A.
    Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces theWarburg effect in melanoma cells.
    BMC Cancer 2016, 16, 134. [PubMed]
  • Diaz-Moralli, S.; Aguilar, E.; Marin, S.; Coy, J.F.; Dewerchin, M.; Antoniewicz, M.R.; Meca-Cortés, O.; Notebaert, L.; Ghesquière, B.; Eelen, G.; et al.
    A key role for Transketolase-like 1 in tumor metabolic reprogramming.
    Oncotarget 2016, 7, 51875–51897 [PubMed]
  • Grimm, M.; Schmitt, S.; Teriete, P.; Biegner, T.; Stenzl, A.; Hennenlotter, J.; Muhs, H.J.; Munz, A.; Nadtotschi, T.; König, K.; et al.
    A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells.
    BMC Cancer 2013, 13, 569. [PubMed]